- Home
- NITO vs ALLR Comparison
NITO vs ALLR Comparison
Compare NITO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- ALLR
- Stock Information
- Founded
- NITO 2009
- ALLR 2004
- Country
- NITO Israel
- ALLR United States
- Employees
- NITO N/A
- ALLR N/A
- Industry
- NITO
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- NITO
- ALLR Health Care
- Exchange
- NITO NYSE
- ALLR Nasdaq
- Market Cap
- NITO 1.9M
- ALLR 2.3M
- IPO Year
- NITO N/A
- ALLR N/A
- Fundamental
- Price
- NITO $0.21
- ALLR $1.25
- Analyst Decision
- NITO
- ALLR
- Analyst Count
- NITO 0
- ALLR 0
- Target Price
- NITO N/A
- ALLR N/A
- AVG Volume (30 Days)
- NITO 882.1K
- ALLR 269.7K
- Earning Date
- NITO 11-14-2024
- ALLR 11-14-2024
- Dividend Yield
- NITO N/A
- ALLR N/A
- EPS Growth
- NITO N/A
- ALLR N/A
- EPS
- NITO N/A
- ALLR N/A
- Revenue
- NITO $175,308.00
- ALLR N/A
- Revenue This Year
- NITO N/A
- ALLR N/A
- Revenue Next Year
- NITO N/A
- ALLR N/A
- P/E Ratio
- NITO N/A
- ALLR N/A
- Revenue Growth
- NITO N/A
- ALLR N/A
- 52 Week Low
- NITO $0.17
- ALLR $1.15
- 52 Week High
- NITO $7.55
- ALLR $666.00
- Technical
- Relative Strength Index (RSI)
- NITO 43.67
- ALLR 35.03
- Support Level
- NITO $0.19
- ALLR $1.16
- Resistance Level
- NITO $0.23
- ALLR $1.53
- Average True Range (ATR)
- NITO 0.02
- ALLR 0.10
- MACD
- NITO -0.00
- ALLR 0.02
- Stochastic Oscillator
- NITO 50.00
- ALLR 28.95
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.